Key facts
- This page summarizes Jonathan Mark Hopper's Form 4 filing for Vericel Corp (VCEL).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 May 2024, 16:07.
Jonathan Mark Hopper - 20 May 2024 Form 4 Insider Report for Vericel Corp (VCEL)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- VCEL
- Reported as of
- 20 May 2024
- Net transaction value
- -$390,400
- SEC form
- 4
- Accepted by SEC
- 21 May 2024, 16:07:32 UTC
- Prior SEC filing
- 26 Feb 2024
- Next SEC filing
- 05 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Jonathan Mark Hopper filed Form 4 for Vericel Corp (VCEL) on 21 May 2024.
Change
- Previous filing in this sequence was filed on 26 Feb 2024.
- Current net transaction value: -$390,400.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VCEL
transaction
Common Stock
Options Exercise
- Transaction value
- $109,500
- Shares
- +10,000
- Change %
- +17%
- Price
- $10.95
- Shares after
- 68,116
- Date
- 20 May 2024
- Ownership
- Direct
- Footnotes
- F1
VCEL
transaction
Common Stock
Sale
- Transaction value
- $499,900
- Shares
- -10,000
- Change %
- -15%
- Price
- $49.99
- Shares after
- 58,116
- Date
- 20 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VCEL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- +10,000
- Change %
- +79%
- Price
- $0.000000
- Shares after
- 22,604
- Date
- 20 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $10.95
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Footnote F2
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2023.
Footnote F3
These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.